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Legendary Inheritance of Sex, Violence 
and Tragedy Surrounding Staphylus
Zeus Semele Minos Pasiphaë
Supreme ruler Mortal priestess King of Crete
Mt. Olympus Asked Zeus to reveal
Married to Hera his glory -
Numerous liaisons Bolts of lightning
Father to Helen led to death
Dionysus Ariadne
God of wine Loved Theseus
Hera had Titan lure who "had no
and attack him joy for her"
remaining heart back on Naxos
into Semele. "Twice born"
Staphylus
God of wine
Traveled with Jason for Golden Fleece
Staphylococcus Aureus
100 abscesses
Some in chains
Some in indigo-colored clumps
Reproduce abscess in mice by 
injection
Aureus: Latin –
 
"gold"
Scot Med J 1998; 43:156-7
Arch Klin Chir 1880; 25:588-
Sir Alexander Ogston
Dionysus
Significance of Bacteremia
 
Caused 
by Staphylococcus Aureus (n=122)
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Skinner & Keefer
Arch Int. Med 1941; 68: 851-75
Antibiotic Resistance in S. aureus
 Following the Great Discovery of Penicillin
Abraham and Chain
Nature 1940; 146:837-
"An enzyme from bacteria
Able to destroy Penicillin"
Extract of E. coli with a
"substance destroying 
property of penicillin" –
penicillinase
Sir Alexander Fleming
S. Aureus Bacteremia
 
and 
Effective Antibiotic Rx
Abboud
 
and Waisbren
 
Arch Intern Med 1959; 104:226-33
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Staphylococcal Toxin* 
by P.N. Panton and F.C. O. Valentine
Denys and Van de Velde
 
in 1895 described destruction of 
WBC after S. aureus injected into pleural cavities of 
rabbits: subsequent anti-leukocidin
 
antibody
7/22 strains: strong leukoidin, weak hemolysis
6/7 severe infections, all 4 "pyemic" cases and
2/4 rapidly fatal after carbuncle
9/22 strains: weak leukocidin, strong hemolysis:
saprophytes
Antisera
 
continuing anti-leukocidin
 
antibodies
"chiefly efficacious with pyemic
 
cases" in man
Lancet 1932 (March 5): 5068
* Gene later found to be on a phage virus integrated to Staph
Penicillin-Resistant S. aureus: 
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Decline of 80/81
80/81: all U.S.
epidemics in
maternity wards
Half of UK outbreaks
1/3 colonized -> BSI
2.5% if non 80/81
Lancet 1959; 1:190-5 Sci Based Med Ann Rev 1966; 157:73
BMJ 1959; 5153:658-62     Lancet 2005; 365:1256-8
S. aureus Resistance Timeline
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Drug introduced Isolation
Precautions
hVISA
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VRSA
AAC 1998; 42:1303-4 IC bundles
kg
IMS 2010
Enterococci
 
Contain Sex-Pheromone
Induced Plasmid Transfer
Plasmid containing
donor
Plasmid free
recipient
consenting (responsive)
-
 
synthesize protein
adhesin
 
facilitating
mating
secrete family of heat-stable
protease 
pheromones (5 to 6) -
 
7 or 8 AA
result -
 
­
 
transfer
frequently 105
 
- 106
 
fold
after transfer -
 
specific plasmid
pheromone shut down
s
Clewell
Cell 1993; 77: 9-12
Eleven Cases of VRSA
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Fully Vancomycin-Resistant 
S. aureus (n=11) 2002-2010
All prior: Vanco
 
Rx, MRSA, VRE
Condition
 
No
 
Age
 
No
D.M.
 
8
 
40s-50s
 
7
Obesity
 
4
 
60s-70s
 
4
ESRD
 
3
Any above
 
10           PHENOTYPE:
Wound
 
10
 

 
Middle-aged adult
Distal
 
7 
 
Insulin resistance
Extremity
 

 
Distal extremity wound
CDC. IDSA Info@society.org
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MRSA Infections in 422 ED Patients -
 
2004
13%
29%
27%
14%
17%
Portland
Los Angeles
Phoenix Albuquerque
Minneapolis
Kansas City
New York
Philadelphia
Charlotte
Atlanta
New Orleans
Moran et al NEJM 2006; 
355:666-74
MRSA
59%
MSSA
41%
USA 300 – 97%
SCC IV, PVL – 98%
USA 300 – 31%
PVL – 42%
S.aureus - 76% SSTI
(MRSA 59%)
Comparison of USA300 and USA400 lethality
 *P<.01, Fisher's exact test.
Montgomery et al JID 2008; 198:561-70
USA 300 More Virulent than USA 400 
Rat Pneumonia Model
Descendants of 80/81 Re-Emerging as CA-
 MRSA:
 
Lessons after 70 years 1940-2010
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PVL (+)
Other phage types
Decline of 80/81
Studies of
Portions of:
7 housekeeping 
genes
8 variable genes
Robinson et al. Lancet 2005; 365:1256-8
USA-300
PVL(+)
So Far…

 
S. aureus
 
infections and modern hospitals 
have been constant companions

 
Resistance patterns arise primarily from 
horizontal gene transfer

 
Evolution of S. aureus
 
is clonal
Some strains (meth ®
 
USA 300 nee
 
PEN 
®
 
80/81) are more virulent, spread more 
rapidly than others, and dominate
The Role of Modern Infection Control
APIC
CDC  decennial meetings
70s
 
80s
 
90s
 
00s
 
2010
UVA
NNIS
SHEA
HIS
SCOPE
SENTRY
Defining the unacceptable (descriptive)
Modelling
 
the possible (analytical)
Testing the interventions (intervention)
Executing good practice (policy)
Milestones in Surgery
16th
 
17th
 
18th
 
19th
 
20th
or earlier                          century
Control bleeding
 Cauterize
 Sutures

 
Abandon Blood-
 
letting

 
Transfusion
Anesthesia
Handwashing
Antisepsis
Ambrose Pare
(1510-1590)
Joseph Lister
(1827-1912)
John Snow
(1813-1858)
Ignaz
Semmelweis
(1818-1865)
Antisepsis
Sterile surgery
Silk Sutures Reduce 
Infecting Dose of S. aureus by 4 logs
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Similar Data:
SubCU
 
Injection
 Skin incision
Elek
 
and Conan Brit J Exp Path 1957; 38: 573-86
Tied suture 3 x 104
 
organisms:
2/2 "very large stitch abscess"
Suture 3 x 102  organisms:
"small stitch abscess"
EFFECT OF SUTURES
Niels
 
Danbolt
 Norwegian dermatologist
 (1900-1984)
Typing -
 
Coagulase
Biochemical Reaction
Necrotizing toxin (skin)
Clumping with specific 
rabbit antibody
Furunculosis
 
(n=50): 77% nasal 
carriage same strain
Recurrent furunculosis
 
(n=24): 22 
had same strain in nose
Healthy  controls –
 
40% carry 
Staphylococci
Courtesy of Niels
 
Chr. Danbolt, PhD, University of Oslo
Median of 55% of  S.aureus
 Surgical Site Infections are Endogenous
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Elimination of Coincident S. aureus Nasal 
and Hand Carriage with Mupirocin
0      Post 4 wks 12 wks 0 Post
Rx Rx
97% same clone
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Nasal
cultures
Controls
Mupirocin
Reagan et al Ann Intern Med 1991; 114:101-6
hand cultures
Intranasal Mupirocin
 
to Prevent 
S.aureus Post-Surgical Infection 
0
1
2
3
4
5
6
Percent
S. aureus
SSI 2.3 2.4
3.7
5.9
Mupirocin
 
placebo            Mupirocin
 
placebo
n=1933         n=1931             n=444             n=447
All        patients               carriers
Perl, Cullen, Wenzel
et al NEJM
 
2002;
346:1871-7
Subset of S.epidermidis Secrete Esp
 Inhibiting S.aureus Nasal Colonization
45% of 960 volunteers S. epi
 
inhibit biofilm
 
of S. aureus
If colonized with inhibitory S. epi
OR=0.30 for S. aureus
 
colonization
Esp, serine protease, plus peptide component of 
innate immune system (hD2)* kill biofilm
Esp
 
intoduced
 
into nares, eliminates S. aureus
 colonization
* Human -defensin
 
2
Iwase et al Nature 20 May 2010
Doi:10.1038/nature09074
Host Genetics May Determine
 
Persistent
 S. Aureus Carriage
Persistant
 
Carriage is Major Risk 
for Auto Infection
Lancet
 
2004; 364:703-5; NEJM
 
2001; 344: 11-16
And is influenced by genetic variation in host 
inflammatory genes
J Infect Dis
 
2008; 197:1244-53
A significant association with persistent carriage (2006 and 
2008) and sets of single nucleotide polymorphisms to 
CRP genes and IL-4 genes.
J Infect Dis
 
2010: 202: 924-34
Hair Follicles as a Niche for S.aureus in 
the Nose
37 cadaver noses
S. aureus
 
culture 9/37
SpA-specific antibodies 
in 8/9
8/8 only in Vestibulum
 
nasi
6 –
 
only outer portions of hair 
follicle
2-deeper parts of hair follicle
ten Broeke-Smits
 
et al
J Hosp Infect 2010; 
76:211-4
Preventing Surgical-Site Infections in 
Nasal Carriers of Staphylococcus aureus
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(n=413)                 (n=504)
n=32
n=17
o ~60% reduction of S aureus infections
o 79% reduction in deep SSI
o 55% reduction in superficial SSIs
Bode LGM, et al. N Engl J Med 2010; 362: 9-17
Screening
Mupirocin
Chlorhexidine
 
baths
Chlorhexidine-Alcohol vs
 
Povidone-
 Iodine for Surgical-Site Antisepsis
o
 
Clean-contaminated surgery, randomly assigned to 
preoperative skin prep with either chlorhexidine-alcohol or 
povidone-iodine paint and scrub
o
 
6 hospitals
o
 
50% of S.aureus
 
SSI prevented without a screening program
RR-Risk Ratio
Darouiche
 
R, et. al N Engl J Med 2010; 362:18-26
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Chlorhexidine-
 
Povidone-
Alcohol (n=391)      Iodine (n=422)
n=409                  n=440
SSI within
30 days
9.5%
16.1%
RR=.59
Estimates of S aureus Infections 
Using Two Different Programs
A horizontal program reduces all infections at a specific anatomic site, whereas a 
Vertical program targets a single organism at that site.
Wenzel R. N Engl J Med. 2010; 362:75-77
So Far…

 
40% of ALL SSIs
 
can be eliminated with a 
change in surgical scrub from Iodophor
 
to 
Chlorhexidine-Alcohol; 60% of S. aureus
 
SSIs
 can be eliminated with Chlorhexidine
 
baths and 
mupirocin
 
Rx of carriers

 
Combining both approaches might yield a 50% 
absolute reduction of all SSIs.
Increasing Antibiotic Resistance 
Strains 1970-2010
Wenzel et al ICHE 2008; 29:1012-8
Health care associated MRSA 2005-2008: 28% decline in US
Kallen
 
et al JAMA 2010; 304:641-8
The Shortcomings of Nasal 
Screening for S. aureus/MRSA
Throat carriage only in S.aureus: 25%
MRSA throat carriage only: 13-15%
Arch Internal Medicine 2009; 169:172-8
Journal of Clinical Microbiology 2008; 46:835
Journal of Clinical Microbiology 227; 45:385
CA-MRSA in Nares
 
Only in 41% 
ICH 2007; 28:966-9
Caveat: Does extranasal
 
carriage have same risk as
nasal carriage?
Decline in Invasive MRSA Infections
CDC’s population-based surveillance 
2005-08: Decline 9.4%/yr 
most prominent for BSIs
28% decline over 4 years
National decline of MRSA BSI
2003-08: 57%
Declines began prior to MRSA-
specific interventions
Possible causes: horizontal programs vs
 
unexplained 
biological trends
JAMA 2010; 304:641-8
JAC 2009; 64 (supp 1):111-7
JAMA 2010; 304:687-9
Controlling Healthcare Associated 
BSI: Vertical vs
 
Horizontal Approach
Subset MRSA
S.aureus Enterococcus Candida                   GNR
Subset VRE          Subset C.                 Subset P.
glabrata aeruginosa
Acinetobacter
Daily 4% Chlorhexidine
 
Baths Decreased 
ICU-related MDR A. baumannii Colonization 
and Bloodstream Infections by 85%
Quasi-experimental design
Before 2/01 –
 
2/02) –
 
after (3/02 –
 
12/03) comparison
Attack rate of A. baumannii
BSI –
 
decreased
4.6% => 0.6% (OR=7.6, p<.001)
Incidence density of A. baumannii
BSI –
 
DECREASED
7.8 to 1.25/1000 pt-days (85% reduction)
Borer et al. J Hosp. Infect 2007; 67:149-55
Could Daily Bathing with 
Chlorhexidine
 
Reduce MRSA and 
VRE Acquisition and Infections?
In quasi-experimental study 
6 mo reg
 
soap => 6 mo chlorhexidine
►MRSA acquisition decreased 32%
► VRE acquisition decreased 50%
► VRE BSI decreased 73%
Crit Care Med 2009; 37:1858-65
Medical College of Virginia Hospital  
Evidence-Based Interventions 
(without active surveillance for MRSA)
Neuroscience, Medical, Surgical ICUs
Device-related BSI, urine infections and VAPs
 
fell 
> 40% in each unit and MRSA infects fell >48% 
in each unit
Edmond et al Am J Infect Control 2008 ; 36:461-3
1 July 2010: 914 days in MRICU wince 
VAP case
66% Reduction in all Catheter-
 related Bloodstream Infections
Incidence
Density
Inf/1000
Cath-days
7.7
1.4
2.7
0
mean
median
103 ICUs
Check list approach
Empowered team
NEJM 2006; 355:2725-32
Bundles to Remove all Central Cath-Related BSIs
Insertion
Aseptic Technique
Maximal Barrier Precautions
Chlorinex/Alcohol Prep
Avoid Femoral Site
Use CVC Check List
Operator Name
Completed CVC Education
Maintenance/Removal
Remove ASAP
Hand Hygiene Before
Clean Part With Alcohol
Avoid 3-Way MPS
Needless Adaptors For Ports
Inspect/Clean Site Daily
Dedicated Lumen For TPNBMJ Qual Saf 2011; 20: 174-80
Figure 1
All or none insertion bundle reliability over time annotated to show identification and 
resolution of causes of incomplete reliability. Detail is given in the online appendix 6. 
Reliability increased between March 2008 and August 2009. 
BMJ Qual Saf 2011;20:174-180. doi:10.1136/bmjqs.2009.037200
Figure 2
U chart. Monthly central-venous-catheter-related bloodstream infection (CRBSI) 
acquisition as rate per device day (number of infections divided
 
by the device 
days/month). The plot demonstrates the common cause variation before the interventions 
start. Special cause variation (downwards shift) is evidenced by
 
a run of >6 points below 
the centre line from February 2008. 
BMJ Qual
 
Saf
 
2011;20:174-180. doi:10.1136/bmjqs.2009.037200
BMJ Qual Saf 2011;20:174-180. doi:10.1136/bmjqs.2009.037200
Reducing Ventilator-Associated
 Pneumonia by 71% -
 
Cohort Study
112 ICUs and 32278 ICU –
 
Months. Bundle:

 
Semi-recumbent position

 
Adjustment of sedation to allow patient to 
follow commands

 
Daily assessment of readiness to extubate

 
Stress Ulcers Prophylaxis

 
Prophylaxis to decrease DVTs
Caveats: No controls; no uniform surveillance 
definition ICHE 2011; 32:305-14
Reducing Ventilator Associated
 Pneumonia by 71% -
 
Cohort Study
Why Do Horizontal Programs Work?
 They Are Population-based: BSI example
Comparison of infection control approaches assuming 10,000 admissions 
and 500-1000 infections (5-10% rate)
Population based
 
MRSA-Subset
Bloodstream infections*
 
50-100
 
7-14†
Number of  deaths estimated**
 
13-25
 
2-4
Attributable deaths***
 
7-13
 
1-2
Lives saved if attributable deaths  
Prevented by 50%
 
4-7
 
1-1
National estimates of lives saved
(assume 35 million admissions –
3500 fold greater than 10,000)
 
14,000-24,500
 
3,500
Wenzel et al. ICHE 2008; 29:1012-18
Controlling Pathogens in the Hospital: 
Vertical vs. Horizontal Approach
MRSA MSSA VRE Acinetobacter
Controlling Pathogens in the Hospital: 
Vertical vs. Horizontal Approach
MRSA MSSA VRE Acinetobacter
Infection Control in 2011
Current data support the argument 
that we have the ability to reduce 
all nosocomial
 
infections by 50%, 
including MRSA, VRE, 
and MDR Acinetobacter
Caveat: Will we begin to see Chlorhexidine
 
resistant 
strains emerge?
See Also:
Infect Control Hosp Epidemiol
 
2011; 32:101-14
From 2011…
How do we prevent the existing infections by 
another 50% in the next 3-4 years… achieving a 
75% total reduction by 2014-2015?
Key Infection Control Safety Question
On a platform of an effective infection control program 
(~ 50% reduction in all
 
infections every 3-4 years), 
what is the incremental value of an adjunctive 
vertical program (MRSA screening)?
Emergence of New Delhi 
Metallo--lactamase
1985
 
1990
 
1995               2000                             2010
Increasing
generations of
Cefalosporins
ESBLs
CTX-M-IS gene
Increasing use of
Carbapenams
K. Pneumoniae
KPCs
BLA NDM-1 gene
Lancet Inf Dis 2010; 10:597-602
NDM-1 in India, Pakistan, and UK
Numbers of carbapenemase-producing 
Enterobacteriaceae
 
referred from UK 
laboratories to the UK Health Protection 
Agency's national reference laboratory from 
2003 to 2009. The predominant gene is 
blaNDM-1, which was first identified in 2008. 
The other group includes diverse producers of 
KPC, OXA-48, IMP, and VIM enzymes. 
Distribution of NDM-1-
 
producing Enterobacteriaceae
 
strains in Bangladesh, India, 
Pakistan, and the UK 
Lancet Inf Dis 2010; 10:597-602
Final Questions

 
Can we begin to think about 
infection control and 
antibiotic resistance as a 
global health problem?

 
Can we construct global 
health policies and strategies 
that benefit the developing 
and developed world 
equally? 
